Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that combining targeted UVA phototherapy with topical 8-methoxypsoralen showed cosmetically acceptable hair regrowth in patients with patchy alopecia areata.

This study demonstrated a method for delivering a photosensitizer, Ammi majus fructuum furocumarines, into hair follicles using calcium carbonate particles, followed by UVA irradiation, which led to significant pigment accumulation, indicating potential improvements for photochemical therapy.

This review discusses nanoparticle-based topical delivery systems for treating skin diseases and presents no new clinical findings; it emphasizes natural polymer-based nanoparticles and future applications like targeted drug delivery.

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

This article reviews drug-induced pigmentation and reports no new clinical findings, highlighting difficulty in confirming drug associations due to factors like delayed onset and polypharmacy.

This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.

This review discusses the efficacy and safety of topical sensitizers for treating alopecia areata and reports no new clinical results; it emphasizes advancements in pediatric use, molecular mechanisms, and targeted delivery methods.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This review discusses guidelines for acitretin use in dermatology, reporting its efficacy in severe psoriasis and recommendations for combination therapies, without providing new clinical trial results.

This article highlights exosome-based targeted drug delivery using DARPin G3 proteins as a promising approach for treating aggressive HER2-positive breast cancer but reports no new clinical results.

In this study, hydroxychloroquine treatment in patients with scleromyxoedema led to complete or partial remission of skin symptoms and improved mobility, though it did not affect paraproteinaemia.

This review discusses current treatments and management strategies for hidradenitis suppurativa, noting the mixed effectiveness of various therapies, including surgery, antibiotics, and hormonal treatments, but reports no new clinical findings.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This review discusses current pharmacological proposals for treating alopecia areata, highlighting the need for individualized treatment plans due to limited clinical trial evidence and potential for spontaneous remission.

This chapter reviews recent developments in vitiligo research, highlighting the role of melanocyte stem cell differentiation and oxidative stress in its management, but reports no new clinical results.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This review discusses newer therapeutic techniques for treating postacne scarring, highlighting their effectiveness for particular grades of scars, and reports no new clinical results.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This review covers nonsteroid-based therapies for alopecia areata, finding potential in PRP, UVR, and laser treatments, but highlights a lack of high-quality evidence for their efficacy.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

This review explores the role of nanotechnology in wound healing, highlighting its potential through antimicrobial properties, selective inflammatory action, angiogenesis promotion, and its use in drug and gene delivery.

Manage vitiligo with treatments, address emotions, and use camouflage techniques.

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

This review discusses the pathogenesis, clinical presentation, diagnosis, and treatment of cutaneous lupus erythematosus, reporting no new clinical findings.

This review discusses the application of liposomes in dermatology, highlighting their therapeutic value for drug stabilization, skin penetration enhancement, and treatment of hair follicle-associated disorders, but reports no new clinical results.

This review discusses the possible impacts of prolactin on skin conditions like psoriasis, alopecia, and stress-related dermatoses, emphasizing the need for further research to explore its therapeutic potential.